Roisman Luiz, Magalhães Fernanda Pedreira, Lavinsky Daniel, Moraes Nilva, Hirai Flávio E, Cardillo José Augusto, Farah Michel Eid
Ophthalmic Surg Lasers Imaging Retina. 2013 Sep-Oct;44(5):465-70. doi: 10.3928/23258160-20130909-08.
To evaluate 810-nm subthreshold diode micropulse (SDM) laser in patients with chronic central serous chorioretinopathy (CSC).
Prospective, randomized, double-blind, sham-controlled pilot trial. Patients were randomized to SDM laser treatment (group 1) or sham procedure (group 2). Primary outcome measure was change in best corrected visual acuity (BCVA); secondary outcome was central macular thickness after 3 months. Laser treatment was performed along the detached area. At the 3-month visit, all patients were evaluated for re-treatment if they met re-treatment criteria.
Fifteen patients were included in this study: five patients in the sham group and 10 in the treatment group. At 3 months, BCVA was significantly enhanced in the treatment group (P = .006) compared with the sham group (P = .498). All patients from the sham group needed treatment after 3 months. An improvement in central macular thickness and leakage on fluorescein angiography was noted in all treated patients (in both groups).
In this limited-size, short-term exploratory study, SDM laser was effective in treating chronic CSC. There was no evidence of retinal damage induced by treatment.
评估810纳米阈下二极管微脉冲（SDM）激光治疗慢性中心性浆液性脉络膜视网膜病变（CSC）患者的效果。
前瞻性、随机、双盲、假对照试验。患者被随机分为SDM激光治疗组（第1组）或假手术组（第2组）。主要观察指标是最佳矫正视力（BCVA）的变化；次要观察指标是3个月后的中心黄斑厚度。激光治疗沿着脱离区域进行。在3个月的随访中，如果所有患者符合再治疗标准，则对其进行再治疗评估。
本研究纳入了15例患者：假手术组5例，治疗组10例。3个月时，与假手术组（P = 0.498）相比，治疗组的BCVA显著提高（P = 0.006）。假手术组的所有患者在3个月后均需要治疗。所有接受治疗的患者（两组）的中心黄斑厚度和荧光素血管造影上的渗漏均有改善。
在这项样本量有限的短期探索性研究中，SDM激光治疗慢性CSC有效。没有证据表明治疗会导致视网膜损伤。
